CC
VOR icon

Clearline Capital’s Vor Biopharma VOR Stock Holding History

Clearline Capital’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.82M Buy
+326,168
New +$4.6M 0.3% 64

Other funds holding VOR

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Clearline Capital's VOR Position: Q1 2026 in Review

Clearline Capital opened a new position in Vor Biopharma (VOR) in Q1 2026: 326,168 shares worth $5.82M. The stake represents 0.3% of the portfolio and ranks #64 among its holdings.

80 funds tracked by Wall St. Rank hold VOR as of Q1 2026.

  • Clearline Capital held 326,168 shares of Vor Biopharma worth $5.82M as of Q1 2026.
  • Vor Biopharma was a new Clearline Capital position in Q1 2026.
  • Vor Biopharma made up 0.3% of Clearline Capital's portfolio in Q1 2026, its #64 holding.
  • 80 funds tracked by Wall St. Rank held Vor Biopharma as of Q1 2026.

Based on Clearline Capital's 13F filing for Q1 2026, filed 15 May 2026.